Louisiana Senate Bill SB70

Louisiana 2017 Regular Session

• Introduced: 3/28/17
• Refer: 3/28/17
• Refer: 4/10/17
• Report Pass: 4/11/17
• Engrossed: 4/18/17
• Refer: 4/19/17
• Report Pass: 5/17/17
• Enrolled: 5/31/17
• Chaptered: 6/12/17
• Passed: 6/12/17

Caption

Makes misbranding or adulteration of drugs under certain circumstances a felony. (8/1/17)

Impact

The adoption of SB 70 would significantly alter the legal landscape concerning the handling and marketing of drugs in Louisiana. By elevating the crime of misbranding from a misdemeanor to a felony, the bill reinforces the state's commitment to regulated drug practices and public health safety. The stricter penalties may discourage fraudulent practices in the pharmaceutical industry and promote accountability among manufacturers and distributors. Furthermore, it aligns state laws with broader national standards aimed at ensuring drug integrity.

Summary

Senate Bill 70 is a legislative proposal introduced during the 2017 Regular Session aimed at addressing the misbranding and adulteration of drugs. The bill specifically targets individuals who engage in such practices with the intent to defraud or mislead, proposing them as felony offenses. The intent behind this legislation is to enhance the penalties associated with drug misbranding and adulteration, thereby promoting safer medical practices and protecting public health. Under SB70, those found guilty of misbranding with malicious intent could face imprisonment for up to five years and fines reaching $10,000.

Sentiment

The sentiment surrounding SB 70 appears to be largely supportive among legislators and stakeholders concerned with public health and safety. Proponents argue that the bill is a necessary update to existing law that will better equip the state to combat deceptive practices in the drug market. However, there may be concerns among critics regarding the potential for over-criminalization and the impact on pharmaceutical businesses, particularly small-scale operators who may struggle with compliance under stricter legal scrutiny.

Contention

While SB 70 garners support, there are notable points of contention regarding its broader implications. Detractors may express concerns about the vague definitions and potential challenges in enforcement. Questions may arise about the adequacy of existing regulatory mechanisms and whether the law might disproportionately affect small businesses involved in healthcare, as the prospect of felony charges could deter legitimate enterprise. These discussions highlight the balance between rigorous public health safeguards and the operational realities of the pharmaceutical and healthcare landscapes.